Immunotherapy combo shows promise against rare skin cancer
NCT ID NCT06151236
First seen Jan 09, 2026 · Last updated May 24, 2026 · Updated 23 times
Summary
This study tests whether giving two immunotherapy drugs (nivolumab and relatlimab) before surgery can improve outcomes for people with stage I to III Merkel cell carcinoma, a rare skin cancer. About 20 adults with resectable tumors will receive the drugs for six weeks, then have surgery to remove any remaining cancer. The main goal is to see how many patients have no cancer cells left in the surgical sample.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MERKEL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Melanoma Institute Australia
RECRUITINGWollstonecraft, New South Wales, 2065, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.